Ranbaxy gains approval to manufacture RAN-Rosuvastatin tablets in Canada
Ranbaxy Pharmaceuticals Canada (RPCI) has received Health Canada approval to manufacture and market RAN-Rosuvastatin tablets to the Canadian healthcare system.
Rosuvastatin is a HMG-COA Reductase Inhibitor (cholesterol-lowering medication).
RPCI, a wholly owned subsidiary of Ranbaxy Laboratories, sells and distributes generic prescription products in the Canadian healthcare system.
RPCI Canada president and general manager Paul Drake said the finished dosage form was developed, and will be manufactured within RLL's Health Canada approved facilities located in India.
"We anticipate making Rosuvastatin tablets available to all classes of trade after April 2 when sufficient supplies are available to meet market demand," Drake added.
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Buy online from $250